Correlation Between Mineralys Therapeutics, and Vor Biopharma
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Vor Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Vor Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and Vor Biopharma, you can compare the effects of market volatilities on Mineralys Therapeutics, and Vor Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Vor Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Vor Biopharma.
Diversification Opportunities for Mineralys Therapeutics, and Vor Biopharma
-0.48 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Mineralys and Vor is -0.48. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Vor Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vor Biopharma and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Vor Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vor Biopharma has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Vor Biopharma go up and down completely randomly.
Pair Corralation between Mineralys Therapeutics, and Vor Biopharma
Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to under-perform the Vor Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Mineralys Therapeutics, Common is 1.09 times less risky than Vor Biopharma. The stock trades about -0.09 of its potential returns per unit of risk. The Vor Biopharma is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest 70.00 in Vor Biopharma on August 24, 2024 and sell it today you would earn a total of 10.00 from holding Vor Biopharma or generate 14.29% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Mineralys Therapeutics, Common vs. Vor Biopharma
Performance |
| Timeline |
| Mineralys Therapeutics, |
| Vor Biopharma |
Mineralys Therapeutics, and Vor Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Mineralys Therapeutics, and Vor Biopharma
The main advantage of trading using opposite Mineralys Therapeutics, and Vor Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Vor Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will offset losses from the drop in Vor Biopharma's long position.| Mineralys Therapeutics, vs. Integrated Drilling Equipment | Mineralys Therapeutics, vs. Xponential Fitness | Mineralys Therapeutics, vs. Lipocine | Mineralys Therapeutics, vs. Delek Drilling |
| Vor Biopharma vs. Monte Rosa Therapeutics | Vor Biopharma vs. Design Therapeutics | Vor Biopharma vs. Erasca Inc | Vor Biopharma vs. Edgewise Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Complementary Tools
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stocks Directory Find actively traded stocks across global markets |